šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
VYNE Therapeutics Inc. (VYNE)
Jul 27, 2026 - VYNE was delisted (reason: merged with YARW)
28.56
+3.11 (12.22%)
Inactive Ā· Last trade price on Jul 27, 2026
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 9, 2026

Summary

YB-101 targets TSHR to address Graves’ disease and TED; early TED data showed rapid hormone changes and dose-dependent proptosis responses. Graves’ Phase II-A and China TED multiple-dose data are expected in 2H 2027, with funding runway into 2030.

Yatin Suneja
Biotech Analyst, Guggenheim

All right, I think we're live. Good afternoon, everyone. Welcome to Guggenheim 3rd Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here at the firm. Our next presenting company is Yarrow. From the company, we have the Chief Executive Officer, Rebecca Frey. Rebecca, why don't you maybe make some opening comments? Yarrow is a relatively new company going after Graves' disease that we all know, but talk about the history, talk about the asset, talk about some of the upcoming milestones, and then I've prepared a little Q&A for you that will go after your some opening comments.

Rebecca Frey
CEO, Yarrow

Happy to. Thanks for having us. I appreciate it. Rebecca Frey, I'm the Chief Executive Officer of Yarrow. We put the company together in 2025. This was incubated inside RTW Investments with the intention of acquiring a first-in-class anti-TSHR asset for the treatment of both Graves' disease and TED. We spent a lot of time in 2025 pursuing the asset and also preparing to launch the company, pursuing financing, et cetera. We also, in that context, we pursued a reverse merger as part of our financing, so we have since completed a reverse merger with VYNE Therapeutics that closed in July. We have raised a total of roughly a little bit north of $350 million across our PIPE and a subsequent follow-on financing that we did in September to fund our programs going forward. We also have recently launched a phase II study in Graves' disease.

Our core thesis is that blocking TSHR with a monoclonal antibody is the most direct way to shut down the disease process in both Graves' disease and thyroid eye disease. If we are successful, this could be the first mechanistic approach to actually have a significant benefit in both Graves' and thyroid eye disease, and we have the most advanced TSHR program currently across both those indications. Our strategy has been to generate clinical data across both indications. Presently, we're doing this through a combined phase II-A/II-B study in Graves' that we've initiated in the U.S., while our partner GenSci is continuing to run a phase I-B study in TED in China.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

We anticipate having data from both our Graves' phase II-A and the GenSci TED phase I-B in the second half of 2027. Those are our major upcoming catalysts.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it. Maybe let's just first focus on the biology a little bit. Where does the idea come from of blocking TSHR? What we have seen on empirical level, why you think is this the most direct approach?

Rebecca Frey
CEO, Yarrow

I'll just start by saying I think this is a really exciting time because the field is opening up in terms of really starting to figure out biologically what's going on and how to tackle these diseases, which have very significant unmet needs. I myself have Graves' disease, so very passionate about that. The underlying biology is pretty well characterized. Both Graves' and TED are diseases that are driven by autoantibodies. Those autoantibodies bind to the TSH receptor, which is expressed on the thyroid and also in the eye. When they bind to the receptor, they overstimulate it. That overstimulation drives the dysregulation of thyroid hormones, and in the eye, also drives the local immune response. That's essentially the disease pathology, and it's a polyclonal disease, so patients can develop a wide range of different isotypes of antibodies that are directed to the TSH receptor.

Conceptually, you can go after the receptor or you can perhaps go after the antibodies. What we believe is that because the disease is purely driven through that receptor location, that by intervening at that point, you have the most direct and efficient way to actually stop the disease process in its tracks, which is what you ultimately want to do from a clinical perspective. We have phase I single-dose data. There's also phase I data that's been generated with another TSHR antibody called K1-70, and across those datasets, you see consistently that this has that potential in terms of even with the single dose, you see a very rapid and deep suppression of signaling at the receptor that's reflective of effectively blocking and interrupting that disease process in a meaningful way.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it. I mean, as you know, FcRn and the degraders are also in this space, but I think at least for FcRns, we know that they do not work well in TED, right? What is the TED angle here? Do you think there is applicability of this mechanism in thyroid eye disease as well?

Rebecca Frey
CEO, Yarrow

Very much so. First of all, I think that we saw the full data set on the FcRns in TED last week, and I think it was obviously alerting and raises some questions, right, about how do you really tackle TED. But the other end of this is that you have the IGF-1R class, which is very limited by safety issues, but they are highly efficacious, and they work by indirectly inhibiting receptor signaling. For us, we see that as validation that if we block TSHR in the eye, which is essentially what is done indirectly by an IGF-1R inhibitor, we have the potential to see improvements in clinical measures of disease. I think that is what is nice about TSHR is it is applicable to both diseases, whereas IGF-1R, A, is limited by toxicity, and B, does not really apply to the thyroid.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it. Was that evident in the phase I study that GenSci conducted? Or maybe just review for us, like, what was that study? What did they see? At least on the thyroid side, there was some data on proptosis. How should we interpret that?

Rebecca Frey
CEO, Yarrow

GenSci is conducting a two-part study in patients with TED in China. These are moderate to severe patients with active TED. The first part of the study, which we have shared the top-line data from, was a single ascending dose study. It is a first-in-human study that went directly into the patient population, and they looked at five different doses of YB-101 versus placebo in an escalating fashion, and obviously evaluated safety and PKPD and efficacy. I think first and foremost, it was informative in that we saw very good safety. There are no dose-limiting toxicities associated with blocking TSHR in this way. The main difference from placebo from a safety perspective is only in the context of thyroid hormones, and we can talk about that.

Yatin Suneja
Biotech Analyst, Guggenheim

Yeah.

Rebecca Frey
CEO, Yarrow

You see very rapid reversal of thyroid hormones with a single dose. Within the first two to three days, you see T4 and T3 declining, and within the first five days, you see TSH increasing after a single dose. That is really a new paradigm because if you look at the little bit of data we have with FcRns on thyroid hormones, for example, TSH takes many, many weeks, if not months, to improve. This is the first approach that has the ability to very rapidly reverse the balance of the thyroid hormones. Even though it is a first-in-human study, we did also look at effects of this approach on proptosis, which is the primary efficacy measure that you would look at in TED, and it is a small sample size, so provide those caveats.

But we observed in a dose-dependent way, very intriguing improvements in proptosis in terms of proptosis responses that was differentiated from placebo, and we are very excited about that. I think directionally, it tells us that we are hitting the target. It is a clear proof of mechanism and really supports going ahead and evaluating this in multiple-dose contexts, which is what GenSci is doing.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

Again, evidence of hitting the target, evidence of potential meaningful activity, and good safety. Very supportive. We took that phase I single-dose data to the FDA and got agreement to go directly to a phase II in Graves'.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it. Maybe before we go to your phase II study, what about the safety consideration? Are there any particular safety sort of events that one should keep an eye on? What about hypothyroidism? How is that managed in patient and the acceptability of that?

Rebecca Frey
CEO, Yarrow

Yeah. We have no, to date, dose-limiting toxicities. The overall safety profile is tracking very favorable.

Again, we were allowed to go directly to a phase II. Any therapeutic that blocks TSHR meaningfully is going to cause hypothyroidism. I would argue that that is the goal. You want to maximally inhibit signaling at the receptor in order to stop the disease process. You should expect to see hypothyroidism. It should be managed in a way that makes it transient, so you give patients T4 replacement in a prompt way in order for them to maintain normal levels of thyroid hormones. That certainly was observed in our single-dose study, and it has been observed with K1-70. Again, should not surprise anyone. It is on-target pharmacology.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

And again, indicative that we are getting the level of disease shutdown and pathway shutdown that we are looking for.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it. Now, going into your phase II-A study, could you just walk us through the design, the arms that you have, what type of dosing you are testing, what type of patient you are going to enroll? Maybe if you can compare and contrast the patient that you are enrolling to the one that FcRns have enrolled.

Rebecca Frey
CEO, Yarrow

Our phase II-A/II-B is called now the Direction GD trial. Again, it is a two-part clinical trial. The II-A part is a proof-of-concept study where we are looking at a few different doses of YB-101 versus placebo in a placebo-controlled design, sorry, across four different cohorts. Patients will be treated every eight weeks with different doses. The primary efficacy readout will be at six months, and the endpoint there is the composite, which is the proportion of patients who are euthyroid and off of ATDs at six months. The patient population is patients with Graves' disease who are well-controlled on ATDs for at least three months. So, they have to be stable, they have to have normal thyroid function to enter, and they have to be on a minimum dose of ATDs.

We have excluded patients who we would consider to have sort of mild disease or possibly remitting disease, really looking to have patients with active disease. The goal of therapy here, again, is to maximize the inhibition and facilitate the elimination of ATD, as that is one of the key components of the regulatory endpoint. The protocol calls for a very structured tapering of ATDs and then initiation of T4 based on changing thyroid hormones. So, not in a discretionary way, but in a controlled way.

Yatin Suneja
Biotech Analyst, Guggenheim

I see.

Rebecca Frey
CEO, Yarrow

That population is perhaps somewhat different from what some other sponsors are currently pursuing, where you have seen studies targeting either subclinically hyperthyroid or overtly hyperthyroid or perhaps sort of refractory uncontrolled patients. Those patients, that is a smaller population, first of all, and to our knowledge, based on some of the groundwork that we did, a harder population from the standpoint of very susceptible to non-compliance with ATDs, which influences their clinical status and overall experience a lot of clinical variability. I would say we have every reason to believe that they would benefit from a TSHR blockade, but what we've decided to do, also in order to position ourselves for a future broad label and to facilitate potentially early treatment as opposed to late treatment, to start in the well-controlled population, have a stable clinical population in order to obtain our clinical POC.

Yatin Suneja
Biotech Analyst, Guggenheim

I see.

Rebecca Frey
CEO, Yarrow

Then we can consider broadening to that more rare subset in the future. But that's sort of how the part one is set up. The part two is the same patient population. We will choose doses for part two based on the data that we generate in part one, and it will be a larger, more classical phase II-B, looking at multiple doses, dose cohorts versus placebo in a double-blinded design. Also looking at six months of treatment and same regulatory endpoint of euthyroid and off of ATDs.

Yatin Suneja
Biotech Analyst, Guggenheim

Okay. In this study, are you testing only? What dosing frequency are you traveling? I know, I think there are four doses. It is Q4W, and are you testing eight weeks?

Rebecca Frey
CEO, Yarrow

Currently, just to kind of walk you through.

GenSci is currently looking at three different doses at a Q8 week interval in their TED study, which is a phase I-B. We have started with two different doses, 180 and 270, at a Q8 week interval in the first two cohorts of our part one. We will have a look at the data. For the second two cohorts, we have tentatively planned to do 400 Q8 and 200 Q4 because we would like to kind of finish filling out our overall dose range, but we also have the flexibility to modify those doses. We have looked essentially at the totality of the data that we have, and we believe that likely supports a Q8 week interval, and that is why we are going forward with that, but also, we can go to Q4 if the data suggests that that would be a reasonable thing to do.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it. Is this study up and running, or are you going to start soon?

Rebecca Frey
CEO, Yarrow

Study was initiated. We dosed our first patient in July.

Yatin Suneja
Biotech Analyst, Guggenheim

Very good.

Rebecca Frey
CEO, Yarrow

We expect to have data second half of 2027 from the first part of the study.

Yatin Suneja
Biotech Analyst, Guggenheim

Yeah. Are you going to disclose data from all four cohorts together? Is that the plan?

Rebecca Frey
CEO, Yarrow

That is the current plan, yes.

Yatin Suneja
Biotech Analyst, Guggenheim

Okay.

Rebecca Frey
CEO, Yarrow

We like to kind of get the whole data set.

Yatin Suneja
Biotech Analyst, Guggenheim

Yeah. Then, obviously, a natural question is, at least on the efficacy side, what is a good readout from your perspective? Are there certain benchmark for us to look at and say, "Hey, look, if you show this is great," and then that's how you move into phase II-A to phase II-B?

Rebecca Frey
CEO, Yarrow

Graves' disease is challenging in that there isn't a long history here of drug development programs.

There hasn't been a drug approved for Graves' since 1950. We don't have a well-validated benchmark to point investors to. One data point is certainly from an uncontrolled study of an FcRn where they saw, for example, a 56% rate of euthyroid and off of ATDs, or at least off of ATDs. I think that's interesting, but feels, for us, when we think about how potent this approach is and the biochemical changes that we see with a single dose, I think we would like to do better than that.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

TED is different. TED, there are very well-established expectations, and as I said before, IGF-1R inhibitors are highly efficacious. I think what our aspiration is to deliver a therapeutic that is similarly efficacious to IGF-1Rs, but lacking in the dose-limiting toxicities that really hinder the completion of treatment courses and broadly just the utilization of the drug. We expect this to have a much more favorable risk-benefit profile in TED.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

Excited about that.

Yatin Suneja
Biotech Analyst, Guggenheim

Very, very interesting. Now, as we think about the commercial dynamic, let me put some numbers in perspective because we have done some analysis. It's a very large number. How do you think about the addressable patient pool? Again, you're running a phase II right now, so I don't want you to comment on the price, but help us understand. The FcRns are expensive, right? Maybe you're not stuck to that price. Talk about that.

Rebecca Frey
CEO, Yarrow

Yeah. It's premature for us to talk about pricing per se. I think our first principle is to try to make this therapy available to as broad of a population as possible, because we really believe that blocking TSHR is the ideal approach, and again, sort of the endgame approach to address both the thyroid and the eye, which are both important. I think we're focused on sort of generating the data first.

Not sort of trying to back into a pricing paradigm, which may be the case for some other companies.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it. Then the patient population, like how big it is? Like, what is the pool?

Rebecca Frey
CEO, Yarrow

Graves' is 1% of the U.S. population. It is a very prevalent disease, and when we think about addressable population, just as a starting point, the vast majority of patients who are diagnosed with Graves' are treated with ATDs. It's viewed to be fairly dangerous to leave Graves' untreated. Our inclusion criteria for our phase II is setting that foundation, hopefully, for future studies and for the label, requires patients to be on ATDs for only three months, and again, at a certain dose. We weren't providing specific numbers here, but just to give you a general sense that it's a pretty large chunk of the initial population, and it's not first line, but it's pretty close to first line if you think about three months of ATDs is not very long.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

I think that gives us a starting point that is quite broad, and again, we're interested in treating early because we believe broadly that this can benefit both the thyroid and the eye, and we think the earlier you treat the eye is better, and potentially there's longer term some opportunity to affect the disease of the eye.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

TED obviously is a pretty well-characterized patient population. You have 40% of Graves' will develop TED, although a lot of endocrinologists tell us that all of their Graves' patients have some degree of eye disease.

Then you have kind of 20%-25% of patients who will get that moderate to severe phenotype that does require intervention, that requires often surgeries and is often treated with steroids or IGF-1Rs. That patient population, at least on the commercial opportunity from looking at currently approved products, is well-characterized.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it. In the phase II-A studies, it's mostly Graves' patient, but are you allowing patients who have TED as well?

Rebecca Frey
CEO, Yarrow

Yes, we are allowing patients who otherwise meet the Graves' criteria to enroll in the Graves' study if they also have TED.

It is not pre-specified or stratified, so it's all comers, and we'll treat that as exploratory subset of patients where we can look at the effects on proptosis over time.

Yatin Suneja
Biotech Analyst, Guggenheim

Yeah.

Rebecca Frey
CEO, Yarrow

Our main TED data set is going to come from China.

Yatin Suneja
Biotech Analyst, Guggenheim

When is that data coming from China? And then, we're going to get both MAD data as well there, right?

Rebecca Frey
CEO, Yarrow

The TED MAD data will come second half of 2027 from China, which is also when we expect to have our Graves' phase II-A.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

Yeah.

Yatin Suneja
Biotech Analyst, Guggenheim

Maybe just one last question then. How are the financials, or how's the capital position right now? How long are you funded till?

Rebecca Frey
CEO, Yarrow

Yeah, so we're really excited to recently complete a follow-on financing and obtain support from both existing and very high-quality new investors. That financing gives us runway into 2030. It fully funds the phase II-B portion of our Graves' program, so on the Graves' side of here, we're fully funded to continue to press forward after we get the II-A readout. It also funds the preparatory work for us to take next steps in TED, so allows us to sort of build out the capabilities and do some groundwork in anticipation of moving into a global program in TED, potentially after we receive the GenSci data in second half of 2027.

Yatin Suneja
Biotech Analyst, Guggenheim

Got it.

Rebecca Frey
CEO, Yarrow

Excited about that too.

Yatin Suneja
Biotech Analyst, Guggenheim

Very good. That's all I had for you, Rebecca. Thank you so much.

Rebecca Frey
CEO, Yarrow

Great. Thank you so much.

Yatin Suneja
Biotech Analyst, Guggenheim

Thank you.